ABEONA THERAPEUTICS INC.

ABEONA THERAPEUTICS INC. (CIK 318306, ticker ABEO) stands as an innovative pharmaceutical preparations company focused on developing gene and cell therapies, including core products that target rare genetic disorders by delivering durable therapeutic solutions through proprietary delivery platforms; its work resonates in the SIC 2830 niche of pharmaceutical preparations, where specialized biologics and advanced therapeutic modalities compete on safety, regulatory compliance, and clinical validation. Serving patients, clinicians, and strategic partners seeking cutting-edge treatments for inherited diseases, the company balances ambitious R&D with patient access goals while keeping a close eye on global regulatory scrutiny and the risks of trial setbacks, manufacturing scale-up, reimbursement volatility, and evolving oversight from the FDA and other authorities. The latest regulatory snapshot comes from the Form 10-Q filed in November 2025, and investors monitoring cadence, liquidity, and progress can view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025